Riskpilot← Back to searchSign inGet full accessKOVALENT Aktiebolag
ABDissolvedOrg 5564172194Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19910 employees
Revenue 2024
SEK 18,7M
-11% vs 2024
EBITDA margin
23.7%
+565% vs 2024
Equity ratio
49.3%
Financial strength
Net profit 2024
SEK 3,3M
+25487% vs 2024
| Revenue | SEK 18,7M | -11% |
| EBITDA | SEK 4,4M | +565% |
| Net profit | SEK 3,3M | +25487% |
| Total assets | SEK 10,8M | -16% |
| Equity | SEK 5,3M | +159% |
| Employees | 0 | — |
Legal name
KOVALENT Aktiebolag
Org number
5564172194
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15 februari 1991
Share capital
SEK 133 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva konsultverksamhet, tillverkning, handel och leasing, allt inom data- och elektronikbranschen, handel med värdepapper samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2024 |
|---|---|---|---|---|---|
| Revenue | 15 947 | 18 426 | 18 750 | 21 045 | 18 720 |
| Staff expenses | — | — | — | −4 580 | −2 254 |
| EBITDA | 1 345 | 1 689 | 1 140 | 666 | 4 429 |
| Depreciation & amort. | −212 | −189 | −92 | −126 | −51 |
| EBIT | 1 133 | 1 500 | 1 048 | 541 | 4 377 |
| Net financials | −272 | −331 | −384 | −516 | −250 |
| Profit before tax | 861 | 1 306 | 873 | 25 | 4 128 |
| Tax | −198 | −273 | −185 | −12 | −852 |
| Net profit | 663 | 1 033 | 688 | 13 | 3 275 |
| Item | 2021 | 2022 | 2023 | 2024 | 2024 |
|---|---|---|---|---|---|
| Total assets | 9 610 | 8 079 | 8 764 | 12 852 | 10 836 |
| Equity | 2 766 | 2 740 | 2 601 | 2 064 | 5 339 |
| Long-term debt | 1 498 | 1 260 | 1 773 | 4 104 | 2 176 |
| Short-term debt | 4 998 | 3 869 | 4 390 | 6 684 | 3 320 |
| Total debt | 6 496 | 5 129 | 6 163 | 10 788 | 5 497 |
EBITDA margin
23.7%
This company
15.8%
Market median
+50% vs market
20212024
Equity ratio
49.3%
This company
38.2%
Market median
+29% vs market
20212024
Return on equity
61.3%
This company
18.4%
Market median
+233% vs market
20212024
Net profit margin
17.5%
This company
8.1%
Market median
+116% vs market
20212024
Asset turnover
1.73×
This company
1.12×
Market median
+54% vs market
20212024
Debt / equity
1.03×
This company
0.62×
Market median
-66% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-07-01 – 2024-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PM Chief Executive Officer | Chief Executive Officer | 2021 |
SH Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
ML Auditor Substitute | Auditor Substitute | 2021 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Novalent AB
KOVALENT Aktiebolag Board members of KOVALENT Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Louise Jonasson | Auditor Substitute | 0 companies |
| Per-Åke Mikael Alfredsson | Chief Executive Officer | 0 companies |
| Sven Henrik Olsson | Chief Auditor | 0 companies |
| Mats Oskar Grapne | Board of Directors | 0 companies |
| Jan Ernst Brattberg | Chairman | 0 companies |